Cost-Effectiveness of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy- A US Payer Perspective
May 1, 2018, 00:00
10.1016/j.jval.2018.04.1335
https://www.valueinhealthjournal.com/article/S1098-3015(18)31638-3/fulltext
Title :
Cost-Effectiveness of a Fixed-Dose Combination Therapy of Lesinurad and Allopurinol for Second-Line Gout Therapy- A US Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)31638-3&doi=10.1016/j.jval.2018.04.1335
First page :
Section Title :
Open access? :
No
Section Order :
586